PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the potential relation between methylation of miR-9-3 and stages of diabetic retinopathy (DR). Additionally, we explored whether miR-9-3 methylation impacts the serum levels of Vascular Endothelial Growth Factor (VEGF).
UNASSIGNED: A cross-sectional study was conducted with 170 participants with type 2 diabetes, including a control group (n = 64) and a diabetes retinopathy group (n = 106), which was further divided into NPDR (n = 58) and PDR (n = 48) subgroups. Epidemiological, clinical, anthropometric, biochemical ELISA assay were analysed. DNA extracted from leukocytes was used to profile miR-9-3 methylation using PCR-MSP.
UNASSIGNED: MiR-9-3 hypermethylated profile was higher in the DR group (p < 0.001) and PDR subgroup compared to DM2 control group (p < 0.001). The hypermethylated profile in the PDR subgroup was also higher compared to NPDR subgroup (p < 0.001). There was no difference between DM2 control and NPDR group (p = 0.234). Logistic regression showed that miR-9-3 hypermethylation increases the odds of presenting DR (OR: 2.826; p = 0.002) and PDR (OR: 5.472; p < 0.001). In addition, hypermethylation of miR-9-3 in the DR and NPDR subgroup was associated with higher serum VEGF-A levels (p = 0.012 and p = 0.025, respectively).
UNASSIGNED: The methylation profile of the miR-9-3 promoter increases the risk of developing PDR. Higher levels of VEGF-A are associated with miR-9-3 hypermethylated profile in patients in the DR and NPDR stages.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-024-01411-9.
UNASSIGNED: A cross-sectional study was conducted with 170 participants with type 2 diabetes, including a control group (n = 64) and a diabetes retinopathy group (n = 106), which was further divided into NPDR (n = 58) and PDR (n = 48) subgroups. Epidemiological, clinical, anthropometric, biochemical ELISA assay were analysed. DNA extracted from leukocytes was used to profile miR-9-3 methylation using PCR-MSP.
UNASSIGNED: MiR-9-3 hypermethylated profile was higher in the DR group (p < 0.001) and PDR subgroup compared to DM2 control group (p < 0.001). The hypermethylated profile in the PDR subgroup was also higher compared to NPDR subgroup (p < 0.001). There was no difference between DM2 control and NPDR group (p = 0.234). Logistic regression showed that miR-9-3 hypermethylation increases the odds of presenting DR (OR: 2.826; p = 0.002) and PDR (OR: 5.472; p < 0.001). In addition, hypermethylation of miR-9-3 in the DR and NPDR subgroup was associated with higher serum VEGF-A levels (p = 0.012 and p = 0.025, respectively).
UNASSIGNED: The methylation profile of the miR-9-3 promoter increases the risk of developing PDR. Higher levels of VEGF-A are associated with miR-9-3 hypermethylated profile in patients in the DR and NPDR stages.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-024-01411-9.
摘要：
■探讨miR-9-3甲基化与糖尿病视网膜病变(DR)分期的潜在关系。此外,我们探讨了miR-9-3甲基化是否影响血管内皮生长因子(VEGF)的血清水平.
■对170名2型糖尿病患者进行了一项横断面研究，包括对照组（n=64）和糖尿病视网膜病变组（n=106），进一步分为NPDR(n=58)和PDR(n=48)亚组。流行病学,临床,人体测量学,生化ELISA分析。从白细胞提取的DNA用于使用PCR-MSP描绘miR-9-3甲基化。
■DR组（p<0.001）和PDR亚组的MiR-9-3高甲基化谱高于DM2对照组（p<0.001）。与NPDR亚组相比，PDR亚组的高甲基化谱也更高（p<0.001）。DM2对照组和NPDR组之间没有差异（p=0.234）。Logistic回归显示miR-9-3高甲基化增加了DR(OR:2.826;p=0.002)和PDR(OR:5.472;p<0.001)的出现几率。此外,DR和NPDR亚组中miR-9-3的高甲基化与较高的血清VEGF-A水平相关(分别为p=0.012和p=0.025).
■miR-9-3启动子的甲基化谱增加了发生PDR的风险。在DR和NPDR阶段的患者中,较高水平的VEGF-A与miR-9-3高甲基化谱相关。
■在线版本包含补充材料，可在10.1007/s40200-024-01411-9获得。
■对170名2型糖尿病患者进行了一项横断面研究，包括对照组（n=64）和糖尿病视网膜病变组（n=106），进一步分为NPDR(n=58)和PDR(n=48)亚组。流行病学,临床,人体测量学,生化ELISA分析。从白细胞提取的DNA用于使用PCR-MSP描绘miR-9-3甲基化。
■DR组（p<0.001）和PDR亚组的MiR-9-3高甲基化谱高于DM2对照组（p<0.001）。与NPDR亚组相比，PDR亚组的高甲基化谱也更高（p<0.001）。DM2对照组和NPDR组之间没有差异（p=0.234）。Logistic回归显示miR-9-3高甲基化增加了DR(OR:2.826;p=0.002)和PDR(OR:5.472;p<0.001)的出现几率。此外,DR和NPDR亚组中miR-9-3的高甲基化与较高的血清VEGF-A水平相关(分别为p=0.012和p=0.025).
■miR-9-3启动子的甲基化谱增加了发生PDR的风险。在DR和NPDR阶段的患者中,较高水平的VEGF-A与miR-9-3高甲基化谱相关。
■在线版本包含补充材料，可在10.1007/s40200-024-01411-9获得。
